Agios Pharmaceuticals (AGIO) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning.

Several other equities analysts also recently commented on AGIO. JPMorgan Chase & Co. reiterated a buy rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. SunTrust Banks reiterated a buy rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Credit Suisse Group increased their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research report on Thursday, November 2nd. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the company a buy rating in a research report on Friday, November 17th. Finally, Cann reiterated a buy rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Agios Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $77.64.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at $69.89 on Tuesday. The company has a market capitalization of $3,322.60, a PE ratio of -11.15 and a beta of 1.83. Agios Pharmaceuticals has a 1 year low of $39.24 and a 1 year high of $76.02.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business’s quarterly revenue was up 26.4% on a year-over-year basis. During the same period last year, the company earned ($1.63) earnings per share. equities analysts expect that Agios Pharmaceuticals will post -6.59 EPS for the current fiscal year.

In other news, CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total transaction of $383,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. Insiders have sold 80,130 shares of company stock valued at $5,561,250 over the last 90 days. 5.43% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of AGIO. Schwab Charles Investment Management Inc. raised its position in shares of Agios Pharmaceuticals by 16.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 96,866 shares of the biopharmaceutical company’s stock worth $4,984,000 after acquiring an additional 13,539 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Agios Pharmaceuticals by 34.0% during the second quarter. Bank of New York Mellon Corp now owns 169,773 shares of the biopharmaceutical company’s stock worth $8,735,000 after acquiring an additional 43,058 shares during the last quarter. Legal & General Group Plc grew its stake in Agios Pharmaceuticals by 25.0% during the second quarter. Legal & General Group Plc now owns 12,517 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 2,506 shares during the period. Principal Financial Group Inc. grew its stake in Agios Pharmaceuticals by 33.8% during the second quarter. Principal Financial Group Inc. now owns 7,083 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 1,789 shares during the period. Finally, Swiss National Bank grew its stake in Agios Pharmaceuticals by 19.7% during the second quarter. Swiss National Bank now owns 66,260 shares of the biopharmaceutical company’s stock worth $3,409,000 after purchasing an additional 10,900 shares during the period. Institutional investors own 94.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://weekherald.com/2018/01/20/agios-pharmaceuticals-agio-raised-to-buy-at-bidaskclub.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply